This topic explores the revolutionary potential of the genome-edited mouse, where endogenous VH and VL genes are replaced by fully human VH and VL genes in situ, enabling the generation of fully human antibody molecules. When combined with Biointron’s AbDrop microfluidic technologyenhanced single B cell screening, this approach allows for the highthroughput and efficient discovery of antibody drug molecules.
Lei Shi, Senior Vice President, Biointron